BioOutsource Launches Comprehensive Range of Off-the-Shelf Testing Methodologies to Support Biosimilar Characterization & Comparability Testing
|| Print ||
|Monday, 23 September 2013 14:45 (UTC + 2)|
Expands Glasgow, Scotland Testing Facilities and Ramps up Commercial Activities in US and Asia-Pacific
BOSTON, Mass., US and GLASGOW, Scotland, UK, September 23, 2013 / B3C newswire / – BioOutsource Ltd. (“BioOutsource”), a leading international Contract Testing Organization (CTO) has consolidated its position as the leading expert in the biological analysis of Biosimilar Monoclonal Antibodies for the biopharmaceutical industry. Strategic internal R&D investment has enabled the creation and launch of a wide range of off-the-shelf testing methodologies to support comparability, stability and lot release testing for Biosimilars. As a result the company has achieved excellent market penetration and sales growth this year and is now working in collaboration with many of the world’s leading Biosimilar companies.
“Our extensive experience in developing and validating cell-based assays and strategic R&D investment has created a niche position for us within the industry, which enables BioOutsource to provide testing solutions that can significantly reduce the time and cost of Biosimilar development programmes,” commented BioOutsource CEO Gerry MacKay. “We are continuing to invest and expand our testing capabilities in Glasgow, Scotland and are significantly increasing commercial activities in the North American and Asia-Pacific regions to support surging demand for Biosimilar characterisation & comparability testing. We are delighted to be working with more than 30 of the top Biosimilar players globally, and look forward to continued strong growth in 2014.”
Dr. Verna McErlane